These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1742853)

  • 1. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
    Robert J; Monnier A; Poutignat N; Hérait P
    Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
    Robert J; David M; Huet S; Chauvergne J
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
    Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion.
    Gotoh T; Tanaka Y; Fujita Y; Hiramori N; Fujii T; Arimoto T; Iwasaki Y; Fukabori T; Nakamura T; Ono N; Nakagawa M
    Jpn J Clin Oncol; 1996 Oct; 26(5):328-34. PubMed ID: 8895673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
    Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
    J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.
    Marchiset-Leca D; Leca FR; Galeani A; Noble A; Catalin J
    Cancer Chemother Pharmacol; 1995; 36(3):239-43. PubMed ID: 7781145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of pirarubicin in human blood.
    Nagasawa K; Kitada N; Tsuji C; Ogawa M; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K
    Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2866-9. PubMed ID: 1464120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.
    Marchiset-Leca D; Leca FR; Galeani A; Noble A; Iliadis A
    Cancer Chemother Pharmacol; 1995; 36(3):233-8. PubMed ID: 7781144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
    Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; McGeary RP; Charles BG
    Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
    Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
    Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.